PBA
OLMA icon

Paradigm Biocapital Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108M Buy
8,670,576
+650,000
+8% +$8.71M 2.03% 17
2026
Q1 		$120M Buy
8,020,576
+476,404
+6% +$10.6M 2.44% 12
2025
Q4 		$189M Buy
7,544,172
+750,000
+11% +$13.3M 4.81% 7
2025
Q3 		$66.5M Buy
6,794,172
+30,000
+0.4% +$180K 1.89% 17
2025
Q2 		$28.8M Buy
6,764,172
+23,000
+0.3% +$103K 1.23% 22
2025
Q1 		$25.3M Sell
6,741,172
-563,798
-8% -$2.84M 1.16% 21
2024
Q4 		$42.6M Buy
7,304,970
+1,801,370
+33% +$18M 1.48% 16
2024
Q3 		$65.7M Sell
5,503,600
-2,400,000
-30% -$30.7M 2.22% 15
2024
Q2 		$85.5M Hold
7,903,600
– – 3.27% 12
2024
Q1 		$89.5M Hold
7,903,600
– – 3.15% 14
2023
Q4 		$111M Buy
7,903,600
+100,000
+1% +$1.34M 5.19% 6
2023
Q3 		$96.4M Buy
7,803,600
+4,072,554
+109% +$41.5M 6.54% 4
2023
Q2 		$33.7M Buy
3,731,046
+1,348,669
+57% +$8.14M 2.6% 17
2023
Q1 		$8.27M Buy
+2,382,377
New +$9.72M 0.78% 24

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Paradigm Biocapital Advisors's OLMA Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Olema Pharmaceuticals (OLMA) stake by 8.1% in Q2 2026, buying an estimated $8.71M and bringing the position to 8,670,576 shares worth $108M. The position accounts for 2.03% of the portfolio, ranked #17.

Paradigm Biocapital Advisors first reported a position in OLMA in Q1 2023 and has held it in 14 quarters since. The position peaked at $189M in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Paradigm Biocapital Advisors held 8,670,576 shares of Olema Pharmaceuticals worth $108M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 650,000 Olema Pharmaceuticals shares in Q2 2026, an estimated $8.71M.
  • Olema Pharmaceuticals made up 2.03% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #17 holding.
  • Paradigm Biocapital Advisors first reported a position in Olema Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Paradigm Biocapital Advisors's Olema Pharmaceuticals position peaked at $189M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.